Citadel Advisors
CURE icon

Citadel Advisors’s Direxion Daily Healthcare Bull 3X ETF CURE Stock Holding History

Citadel Advisors’s Portfolio CURE Stock Details CURE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Buy
17,600
+5,800
+49% +$630K ﹤0.01% 6564
2025
Q4 		$1.32M Sell
11,800
-1,800
-13% -$184K ﹤0.01% 6802
2025
Q3 		$1.14M Sell
13,600
-6,100
-31% -$475K ﹤0.01% 7261
2025
Q2 		$1.55M Buy
19,700
+5,200
+36% +$420K ﹤0.01% 6191
2025
Q1 		$1.55M Buy
14,500
+5,000
+53% +$532K ﹤0.01% 6034
2024
Q4 		$877K Buy
9,500
+5,200
+121% +$586K ﹤0.01% 7326
2024
Q3 		$573K Buy
4,300
+3,200
+291% +$412K ﹤0.01% 7975
2024
Q2 		$128K Sell
1,100
-800
-42% -$90.1K ﹤0.01% 10559
2024
Q1 		$238K Sell
1,900
-6,200
-77% -$721K ﹤0.01% 9955
2023
Q4 		$824K Sell
8,100
-2,200
-21% -$197K ﹤0.01% 7072
2023
Q3 		$912K Buy
10,300
+3,700
+56% +$364K ﹤0.01% 6765
2023
Q2 		$660K Sell
6,600
-7,500
-53% -$746K ﹤0.01% 7329
2023
Q1 		$1.35M Buy
14,100
+9,400
+200% +$943K ﹤0.01% 6128
2022
Q4 		$539K Sell
4,700
-300
-6% -$32.4K ﹤0.01% 8082
2022
Q3 		$422K Sell
5,000
-4,000
-44% -$413K ﹤0.01% 8841
2022
Q2 		$928K Sell
9,000
-5,600
-38% -$631K ﹤0.01% 7198
2022
Q1 		$1.91M Buy
14,600
+1,100
+8% +$131K ﹤0.01% 6196
2021
Q4 		$1.96M Buy
13,500
+900
+7% +$109K ﹤0.01% 6292
2021
Q3 		$1.35M Buy
12,600
+4,500
+56% +$541K ﹤0.01% 7360
2021
Q2 		$847K Buy
8,100
+700
+9% +$67.2K ﹤0.01% 8780
2021
Q1 		$618K Buy
+7,400
New +$597K ﹤0.01% 9225
2020
Q4 		– Sell
-4,700
Closed -$296K – 10978
2020
Q3 		$296K Sell
4,700
-45,900
-91% -$2.88M ﹤0.01% 8149
2020
Q2 		$2.75M Sell
50,600
-51,400
-50% -$2.73M ﹤0.01% 4012
2020
Q1 		$4.07M Buy
102,000
+98,700
+2,991% +$6.22M ﹤0.01% 2997
2019
Q4 		$243K Sell
3,300
-9,400
-74% -$574K ﹤0.01% 7896
2019
Q3 		$642K Buy
12,700
+1,200
+10% +$63.7K ﹤0.01% 6319
2019
Q2 		$645K Buy
11,500
+2,900
+34% +$150K ﹤0.01% 6413
2019
Q1 		$478K Sell
8,600
-6,500
-43% -$346K ﹤0.01% 6861
2018
Q4 		$719K Sell
15,100
-700
-4% -$39.3K ﹤0.01% 5821
2018
Q3 		$1.05M Buy
15,800
+4,400
+39% +$252K ﹤0.01% 5452
2018
Q2 		$517K Buy
11,400
+5,600
+97% +$250K ﹤0.01% 6307
2018
Q1 		$250K Buy
5,800
+1,300
+29% +$65.3K ﹤0.01% 7013
2017
Q4 		$210K Buy
+4,500
New +$208K ﹤0.01% 7036

Other funds holding CURE

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's CURE Position: Q1 2026 in Review

Citadel Advisors sold out of Direxion Daily Healthcare Bull 3X ETF (CURE) in Q1 2026, closing a stake of 16,309 shares — an estimated $1.77M sold.

Citadel Advisors first reported a position in CURE in Q3 2015 and held it in 39 quarters. The position peaked at $9.73M in Q2 2019. 15 funds tracked by Wall St. Rank hold CURE as of Q1 2026.

  • Citadel Advisors reported no remaining Direxion Daily Healthcare Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 16,309 Direxion Daily Healthcare Bull 3X ETF shares in Q1 2026, an estimated $1.77M.
  • Citadel Advisors first reported a position in Direxion Daily Healthcare Bull 3X ETF in Q3 2015 and held it in 39 quarters.
  • Citadel Advisors's Direxion Daily Healthcare Bull 3X ETF position peaked at $9.73M in Q2 2019.
  • 15 funds tracked by Wall St. Rank held Direxion Daily Healthcare Bull 3X ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.